
Illinois health care providers may no longer order the monoclonal antibodies bamlanivimab and etesevimab until further notice due to rising prevalence in Illinois of the SARS-CoV-2 P.1 variant, which is not susceptible to the combination therapy, the Office of the Assistant Secretary for Preparedness and Response announced.